Strota / MANKIND / Quarterly results

Mankind Pharma Q1 FY27 Results: Revenue, Profit and Share Price Reaction

Mankind Pharma's quarterly results from its filings with NSE, consolidated, with how the share price moved on each announcement.

Q1 FY27 (quarter to 30 Jun 2026): revenue ₹4,031 crore (+12.9% year on year), net profit ₹574 crore (+31.0% year on year), EPS ₹13.76. Announced 30 Jul 2026, 8:15 pm IST. The shares fell 4.13% on 31 Jul 2026, 4.40 points worse than the Nifty 50. Next results board meeting: 26 Oct 2026.
Revenue
₹4,031 cr
YoY +12.9% · QoQ +17.1%
Net profit
₹574 cr
YoY +31.0% · QoQ +3.6%
EPS (basic)
₹13.76
YoY +29.6%
Share price reaction
-4.1%
31 Jul 2026 · vs Nifty -4.4%

Revenue and net profit by quarter

RevenueNet profit
Q4 FY25 Revenue: ₹3,079 cr Q4 FY25 net profit: ₹425 cr Q4 FY25 Q1 FY26 Revenue: ₹3,570 cr Q1 FY26 net profit: ₹438 cr Q1 FY26 Q2 FY26 Revenue: ₹3,697 cr Q2 FY26 net profit: ₹512 cr Q2 FY26 Q3 FY26 Revenue: ₹3,567 cr Q3 FY26 net profit: ₹409 cr Q3 FY26 Q4 FY26 Revenue: ₹3,443 cr Q4 FY26 net profit: ₹554 cr Q4 FY26 Q1 FY27 Revenue: ₹4,031 cr Q1 FY27 net profit: ₹574 cr Q1 FY27

Every quarter

QuarterAnnouncedRevenueYoYNet profitYoYMarginEPSPrice reaction
Q1 FY2730 Jul 2026, 8:15 pm IST 4,031+12.9%574+31.0% 14.2%13.76 -4.1%
Q4 FY2619 May 2026, 11:23 pm IST 3,443+11.8%554+30.4% 16.1%13.44 +3.7%
Q3 FY263 Feb 2026, 7:37 pm IST 3,567—409— 11.5%9.9 -3.4%
Q2 FY266 Nov 2025, 9:35 pm IST 3,697—512— 13.8%12.39 -2.0%
Q1 FY2631 Jul 2025, 9:48 pm IST 3,570—438— 12.3%10.62 -0.0%
Q4 FY2521 May 2025, 9:32 pm IST 3,079—425— 13.8%10.19 -3.6%

₹ crore. Consolidated figures; net profit is the share attributable to the company's owners where reported. Margin = net profit ÷ revenue. Year-on-year compares with the same quarter a year earlier.

How MANKIND shares react to results

Across the last 6 results here, the shares rose on 1 and fell on 5. The average move was -1.60%, and the average size of the move either way 2.82%; the biggest was -4.13% after the Q1 FY27 results. In the 2 quarters where profit grew year on year, the shares rose once.

The reaction is the close of the first session that could trade on the news (the announcement day if it came before 3:30 pm, otherwise the next session) against the previous close. A few results don't explain a stock's move; markets also price guidance, commentary and what was expected.

Questions

What were Mankind Pharma's Q1 FY27 results?

For the quarter to 30 Jun 2026, Mankind Pharma reported revenue of ₹4,031 crore (+12.9% year on year) and net profit of ₹574 crore (+31.0%), with basic EPS of ₹13.76.

How did Mankind Pharma shares react to the Q1 results?

They fell 4.13% on 31 Jul 2026, the first session that could trade on the results (announced after the close); that was 4.40 points worse than the Nifty 50 that day.

When is Mankind Pharma's next results date?

The board meets on 26 Oct 2026 to consider results, according to the company's intimation to NSE.

Do Mankind Pharma shares usually rise after results?

In the last 6 results here they rose 1 times and fell 5 times, moving 2.82% on average either way.

About this data

From Mankind Pharma's Integrated Filing (Financials) XBRL with NSE, which listed companies use for quarterly results since 2025; announcement times are NSE's broadcast times (IST). Share prices are NSE closing prices. See MANKIND stock page for price, open interest and deals, all results declared this week and the results calendar, and MANKIND dividend history.